Palbociclib
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.
中文名 帕博西林,帕博昔布 外文名Palbociclib 原研企业 美国辉瑞制药(Pfizer) 药物类别 吡啶并嘧啶衍生化的CDK抑制剂
Palbociclib的生物活性
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases.
化学信息:
外观:黄色至灰白色晶状固体
分子量: 447.53
分子式: C24H29N7O2
CAS号: 571190-30-2
溶剂/溶解度: DMSO
晶型:2种,A和B,均为无水晶体
储存条件: 参考CoA中推荐的条件进行储存。 |